glp 1 parkinson's disease and GLP-1 Disease: Research, Benefits and Risks GLP-1 Receptor Agonists in Neurodegeneration: – Are GLP-1 diabetes drugs like

There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape

doi: 10.1016/j.ejphar.2020.173449 77 LiSFengLLiGLiuRMaCWangLet al

Am J Physiol (1996) 271:E45864

Further research is required to gain a more comprehensive understanding of this aspect